Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$5.03 ▼ -0.14
(-2.71%)
MKT CAP: $31.4M • VOL: 47.2K
52W L $4 52W H $14
ROARABLE / RQD
E • 26/100
PIOTROSKI
2 / 9
ALGS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.2M | $3.6M | $6.2M |
| YoY Revenue Growth % | -39.5% | -41.7% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$88.0M | -$89.2M | -$88.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$24.2M | -$131.2M | -$87.7M |
| EBITDA (Normalized) | — | -$89.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$82.5M | -$80.7M | -$79.0M |
| Capital Expenditures (CapEx) | — | $130.0K | — |
| Free Cash Flow (FCF) | -$82.5M | -$80.9M | -$79.0M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $18.3M | $37.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $53.5M | -$29.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ALGS.